Bravo
Devicewireless pH monitoring over 96 hours
NCT Number: NCT03417817
First introduced over 40 years ago, the 24-hour catheter-based pH studies have previously been found to be the gold standard in the diagnosis of gastro-oesophageal reflux disease (GORD). In 2003, the Bravo has revolutionised the study of GORD, allowing patients an improved comfort and ability to perform activities of daily living.
The backflow of gastric acid (acid exposure) in the oesophagus is monitored by a tiny pH sensor located in a capsule which is pinned temporarily to the wall of the oesophagus at the time of endoscopy. Normal measurements for acid exposure are established for 48-hour studies. However, the investigators' studies have shown that extending the duration of recording to 96 hours further improved the diagnostic yield for GORD in patients with negative 24-hour catheter-based tests
The 96-hour recording is the current standard of care, despite the lack of normal ranges for this duration of the recording. The basis for the diagnosis of GORD in 96-hours studies is based on the 48-hours normal controls. The objective of this study is to determine the normal values for oesophageal acid exposure using the wireless pH recording apparatus over 96 hours in asymptomatic healthy subjects with unrestricted activity and diet.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
This is a single centre study on healthy subjects to determine the normal values for oesophageal acid exposure using the wireless pH monitoring over 96 hours. The investigators anticipate the recruitment of 50 participants over 10 months.
Subjects without reflux symptoms, either healthy volunteers (hospital staff and medical students) or people referred for gastroscopy in the context of other conditions (e.g. iron deficiency anaemia, suspected coeliac disease) will be recruited. An interview will be arranged where the subjects will be assessed for gastro-oesophageal symptoms using the Montreal GORD consensus definition and dysphagia based on the Hospital Odynophagia Dysphagia Questionnaire. Once confirmed asymptomatic, participants will be offered an appointment for enrolment. If candidates are asymptomatic, the subjects will be invited to a further interview where the procedure, risks and benefits will be discussed in detail. If participants fulfil the inclusion and exclusion criteria then participants will be given the option to enrol in the study. If at any point, participants wish to withdraw from the study, they have the option to do so without explaining why.
Once recruited the following assessments and interventions will take place:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
wireless pH monitoring over 96 hours
Time frame: 4 days
Time frame: 3 days
Time frame: 1 day
Acid exposure measured as percent total time pH < 4
Time frame: 1 day
Acid exposure measured as percent Upright time pH < 4
Time frame: 1 day
Acid exposure measured as percent Supine time pH < 4
Time frame: 1 day
Acid exposure measured as number of reflux episodes
Time frame: 1 day
Acid exposure measured as number of reflux episodes ≥ 5 min
Time frame: 1 day
Acid exposure measured as the longest reflux episode (minutes)
Time frame: 1 day
Acid exposure measured as Bravo "cut off" value
Guy's and St Thomas' NHS Foundation Trust
Other
Measurement of Acid Exposure in Healthy Subjects Using 96 Hours Wireless pH Monitoring (Bravo™)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05556824
Deglutition Disorders, Digestive System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT03596411
Deglutition Disorders, Digestive System Diseases
Nice, Alpes Maritimes, France
View Trial DetailsNCT02083952
Apnea, Arrhythmias, Cardiac
Ridgewood, New Jersey, United States
View Trial DetailsNCT06329583
Deglutition Disorders, Digestive System Diseases
Jacksonville, Florida, United States
View Trial Details